These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 929037)

  • 1. [Abnormal movements caused by L-DOPA in patients with Parkinson's disease: correlation with the plasma concentrations of DOPA and O-methyl-DOPA].
    Lhermitte F; Agid Y; Feuerstein C; Serre F; Signoret JL; Studler JM; Bonnet AM
    Rev Neurol (Paris); 1977; 133(8-9):445-54. PubMed ID: 929037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Results of determination of plasma methoxydopa in parkinsonian patients with or without dyskinesia induced by L-Dopa].
    Perret J; Feuerstein C; Pellat J; Serre F; Gavend M; Tanche M
    Rev Neurol (Paris); 1977 Nov; 133(11):627-36. PubMed ID: 601391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ["Beginning and end of dose" dyskinesias caused by L-DOPA].
    Lhermitte F; Agid Y; Signoret JL; Studler JM
    Rev Neurol (Paris); 1977 May; 133(5):297-308. PubMed ID: 897439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Abnormal movements of patients with Parkinsonism treated with L-dopa and anomalies of dopamine metabolism].
    Lhermitte F; Rosa A; Comoy E
    Rev Neurol (Paris); 1977 Jan; 133(1):3-11. PubMed ID: 847319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dyskinesia caused by L-DOPA].
    Derkinderen P; Vidailhet M
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S92-101. PubMed ID: 12690668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P; Tremblay L; Féger J; Hirsch EC
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease].
    Kannari K; Kurahashi K; Tomiyama M; Maeda T; Arai A; Baba M; Suda T; Matsunaga M
    No To Shinkei; 2002 Feb; 54(2):133-7. PubMed ID: 11889759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
    Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
    Zimmerman TR; Sage JI; Lang AE; Mark MH
    Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Onset-and end-of-dose dyskinesias induced by L-dopa treatment in a patient with juvenile parkinsonism].
    Katsuki T; Shimizu N; Mizuno Y
    No To Shinkei; 1984 Dec; 36(12):1201-5. PubMed ID: 6529518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical pharmacology of dyskinesias induced by L-dopa in Parkinsonian patients].
    Rascol O; Brefel-Courbon C; Blin O
    Therapie; 1998; 53(1):43-8. PubMed ID: 9773099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioids and motor complications in Parkinson's disease.
    Samadi P; Bédard PJ; Rouillard C
    Trends Pharmacol Sci; 2006 Oct; 27(10):512-7. PubMed ID: 16908075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term problems of levodopa therapy in Parkinson disease].
    Albani C; Asper R; Baumgartner G
    Schweiz Med Wochenschr; 1987 Mar; 117(10):347-53. PubMed ID: 3105050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.
    Mazzella L; Yahr MD; Marinelli L; Huang N; Moshier E; Di Rocco A
    Parkinsonism Relat Disord; 2005 May; 11(3):151-5. PubMed ID: 15823479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease.
    Rice JE; Antic R; Thompson PD
    Mov Disord; 2002 May; 17(3):524-7. PubMed ID: 12112201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma O-methyldopa in levodopa-induced dyskinesias. A bioclinical investigation.
    Feuerstein C; Serre F; Gavend M; Pellat J; Perret J; Tanche M
    Acta Neurol Scand; 1977 Dec; 56(6):508-24. PubMed ID: 605774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation.
    Picconi B; Paillé V; Ghiglieri V; Bagetta V; Barone I; Lindgren HS; Bernardi G; Angela Cenci M; Calabresi P
    Neurobiol Dis; 2008 Feb; 29(2):327-35. PubMed ID: 17997101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.